Evgen Pharma PLC (EVG)

London
4.30
-0.15(-3.37%)
  • Volume:
    109,034
  • Bid/Ask:
    4.30/4.40
  • Day's Range:
    4.30 - 4.39

EVG Overview

Prev. Close
4.45
Day's Range
4.3-4.39
Revenue
-
Open
4.36
52 wk Range
2.83-7.8
EPS
-0.012
Volume
109,034
Market Cap
11.82M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
959,805
P/E Ratio
-3.66
Beta
1.73
1-Year Change
-4.3%
Shares Outstanding
274,888,117
Next Earnings Date
05 Jun 2023
What is your sentiment on Evgen Pharma PLC?
or
Vote to see community's results!

Evgen Pharma PLC Company Profile

Evgen Pharma PLC Company Profile

Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the clinical development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. Its Sulforadex technology enables sulforaphane to be delivered as a stable, solid, active ingredient in an oral pharmaceutical product. Its lead drug, SFX-01, exploits sulforaphane’s activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. The Company pipeline includes SFX-01 and breast cancer, SFX-01 and glioma, and SFX-01 and SHP2. SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The Company is also researching a range of synthetic, stabilized novel analogues of sulforaphane to advance the pharmaceuticals.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • just won 2 million bullish
    2